Truist Securities Reiterates Buy on Vertex Pharmaceuticals, Raises Price Target to $550
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $508 to $550.
August 05, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Vertex Pharmaceuticals and increased the price target from $508 to $550.
The reiteration of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100